FzioMed

Development and commercialisation of synthetic, absorbable surgical biomaterials

FzioMed is a privately held medical device company founded 1996 by Ronald F. Hynes.

John Krelle, President and CEO
Richard Berg, Ph.D., VP of Research and Development and CSO
Todd Fanning, VP of Sales

Ron Haynes, Chairman
Kevin K. Sidow
James R. Peters

231 Bonetti Drive
San Luis Obispo, California 93401
USA
Phone: +1-805-546-0610
Fax: +1-805-546-0571

Oxiplex® is FzioMed’s core technology platform. It consists of biocompatible polymers and is ideal for use in surgery and other medical applications. The material has been shown to adhere well to tissues. It stays in place long enough to prevent adhesion bands from connecting apposing structures. In addition, it clears naturally from the body. It can, for example, adapted to drug delivery processes, as haemostatic agent, injectables, coatings, tissue.

The company currently undertakes a randomised, multicentre clinical trial to determine the safety and effectiveness of Oxiplex®/SP Gel in the USA. The gel is designated for the reduction of pain and symptoms following lumbar disc surgery.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.